This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Sandbox bcce8
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
==β-Glucuronidase== | ==β-Glucuronidase== | ||
<StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''> | <StructureSection load='3hn3' size='340' side='right' caption='Ribbon diagram of human β-glucuronidase' scene=''> | ||
| - | <StructureSection load='3lpf' size='340' side='right' caption='Ribbon diagram of ''E. coli'' β-glucuronidase' scene=''> | ||
This tutorial illustrates the quaternary structures of the human and ''E. coli'' β-glucuronidase enzyme. | This tutorial illustrates the quaternary structures of the human and ''E. coli'' β-glucuronidase enzyme. | ||
| Line 11: | Line 10: | ||
== Relevance == | == Relevance == | ||
| - | Deficiencies in the human form of β-glucuronidase is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal. | + | Deficiencies in the human form of β-glucuronidase (<scene name='59/596447/Human_bglucuronidase/1'>TextToBeDisplayed</scene>) is associated with a disease known as Sly Syndrome (AKA Mucopolysaccharidosis VII -- MPS VII). This disease is characterized by mental retardation, short stature, macrocephaly, and enlarged joints. As is commonly seen with genetic disorders, patients with this disease present a spectrum of symptom severity, but the disease is always ultimately fatal. |
| - | The ''E. coli'' form of β-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'> | + | The ''E. coli'' form of β-glucuronidase (<scene name='59/596447/E_coli_b-glucuronidase/1'>ribbon diagram</scene>) is associated with the side effects seen with administration of the cancer chemotherapy drug CPT-11. This drug gets converted to SN38, a topoisomerase inhibitor, by the liver. The body adds a glucuronide group to this molecule (now SN38-G) to mark it for elimination, which partially occurs through the intestine. Once in the intestine, bacterial β-glucuronidase cleaves the glucuronide from the SN38-G, releasing the SN38 into the intestinal lumen. The released SN38 prevents cell division, compromising the epithelial lining of the intestines, a painful and dangerous side-effect of CPT-11 administration. |
Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme. | Selective inhibition of bacterial β-glucuronidase is desired to alleviate this side-effect of CPT-11 treatment, hopefully without inhibiting the human form of the enzyme. | ||
Revision as of 14:51, 6 August 2014
β-Glucuronidase
| |||||||||||
